& Gomez-Pinilla, F
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
Pain reduction and improved mobility within 1 to 3 weeks for soft tissue injuries
Dutta, D., Nagendra, L., Harish, B., Sharma, M., Joshi, A., Hathur, B., & Kamrul-Hasan, A
See my options Research Snapshot Head-to-head comparison Regulatory status, labels, trial records, and sponsor updates can change quickly for obesity-drug pipeline pages
Contraindications: XIAFLEX is contraindicated in the treatment of Peyronies plaques that involve the penile urethra due to potential risk to this structure and in patients with a history of hypersensitivity to XIAFLEX or to collagenase used in any other therapeutic application or application method Corporal Rupture or Other Serious Injury to the Penis: Injection of XIAFLEX into collagen-containing structures such as the corpora cavernosa of the penis may result in damage to those structures and possible injury such as corporal rupture (penile fracture)